← Back to Clinical Trials
Recruiting NCT05853783

Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™

Trial Parameters

Condition Mouth Diseases
Sponsor Proteocyte Diagnostics Inc.
Study Type OBSERVATIONAL
Phase N/A
Enrollment 180
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-01-01
Completion 2024-12
Interventions
STRATICYTE™ Test

Brief Summary

The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective cohort of patients who received biopsies.

Eligibility Criteria

Inclusion Criteria: * From the archive, any patient who presents with clinically evident oral lesions and biopsy-proven dysplasia (punch or scalpel biopsies; any grade or classification system) * Patients with initial oral lesions with epithelial atypia suspicious for neoplasia, with: * No histological evidence of cancer with clinical follow-up data for a period of at least five years; or * OSCC development (histologic or documented evidence of invasive cancer). * Patients who had archived biopsy tissue blocks of a previous oral lesion(s) meeting the above criteria and retained at the same clinical center. Exclusion Criteria: * Patients with oral lesions or dysplasia with no indication of OSCC development or follow-up data of less than five years in non-OSCC patients. * Patients diagnosed with oral epithelial dysplasia concomitant with OSCC at the time of the biopsy's original pathology report or a subsequent clinical note of cancer progression within three months post-biopsy.

Related Trials